COMPANY PROFILE

Verge Genomics

Explore full profile

Pioneering a better drug discovery process using systems biology to improve the lives of people

San Francisco, United StatesFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Verge Genomics

Verge Genomics is a biotechnology startup that leverages advanced technologies such as human genomics, machine learning, and biological engineering to develop innovative drugs. The company operates in the pharmaceutical industry, specifically focusing on the development of treatments for severe diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's Disease, and Frontotemporal Dementia.

Verge Genomics' unique approach involves using human tissue to build one of the world's largest proprietary multi-omics databases, rather than relying on animal or cell models. This allows them to map the complex causes of diseases more accurately. The company uses machine learning, a type of artificial intelligence that enables computers to learn from and make decisions based on data, to analyze this information and develop potential drug candidates.

Their business model revolves around the development and commercialization of these proprietary drug candidates. Their first drug, VRG50635, a small molecule inhibitor of PIKfyve, has already entered the clinical stage for the treatment of ALS. This drug was discovered using Verge's all-in-human, AI-powered platform, CONVERGE®, which allowed it to move from research to clinic in just four years.

Verge Genomics serves a broad range of clients, including healthcare providers and patients suffering from the diseases they target. Their revenue is generated through the successful development and sale of their drug candidates.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: San Francisco, United States
Employees: 27
Open positions: None listed
Dealroom signal: 61.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Genetics and genomics, Core AI, Spinout, Genome Engineering, AI Drug Discovery, Techbio Drug Discovery, AI Applications, YC S15, DT and LS
Investment activity: 1 company, latest Jan 2019
Capital deployed: $35M
Preferred round: LATE VC
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Dec 2021	$98M	$392M	Threshold Ventures · Section 32 · ALS Investment Fund · Lifeforce Capital	↗
SERIES AOther financing	Jul 2018	$32M	$128M	Threshold Ventures · Great Oaks Venture Capital · WuXi AppTec · Agent Capital	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Verge Genomics website traffic

Latest recorded traffic for Verge Genomics is 3K monthly website visits, down 28.6% over the last three months. Verge Genomics's team declined 18.2% over the past year.

Latest monthly visits3K 3-month web change-28.6% 1-year team growth-18.2%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational	51	$16M	$32M
PHPharmEnablePharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery	Cambridge, United Kingdom	Operational
TATurbine AISimulation-driven drug discovery company delivering population targeted cancer therapies	Budapest, Hungary	Operational
IMInSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases	Cambridge, United States	Operational
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
ALALLOXHarnessing the power of genetics and AI to learn the biophysical parameters governing protein function	Barcelona, Spain	Operational
ADAMPLY DiscoveryNovel Biologics. Designed by Evolution. Discovered by AI	Belfast, United Kingdom	Operational